🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Intrarosa 6.5 mg pessary

    Istituto Gentili S.r.l.

    Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).

    phase 3 small molecule active

    1 trial

  2. Intravenous Ibuprofen

    CUMBERLAND PHARMACEUTICALS INC

    Postoperative Pain

    phase 3 small molecule active

    1 trial

  3. Intravenous Immunoglobulin

    Option Therapeutics

    Autoimmune Epilepsy

    phase 3 small molecule terminated

    1 trial

  4. Intravitreal Aflibercept Injection (IAI)

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  5. Intravitreal aflibercept injection [IAI]

    Regeneron UK Limited

    Nonproliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  6. Investigator's choice of Chemotherapy

    Zentalis Pharmaceuticals

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  7. Irinotecan liposome、5-Fluorouracil、Leucovorin

    Jian Li

    Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

    phase 3 small molecule completed

    1 trial

  8. Iron (27 mg) - folic acid (600 ug)

    United Therapeutics Europe Ltd

    Infant Mortality

    phase 3 other completed

    1 trial

  9. Isoniazid with Ethambutol

    United Therapeutics Europe Ltd

    Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial

  10. Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, C1-esterase inhibitor

    Maze Therapeutics

    acute hereditary angioedema attacks

    phase 3 small molecule active

    1 trial

  11. Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, Panzyga 100 mg/ml Infusionslösung

    Maze Therapeutics

    Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia.

    phase 3 small molecule active

    1 trial

  12. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)

    phase 3 small molecule active

    1 trial

  13. Ivonescimab Injection

    Summit Therapeutics

    Non-Small Cell Lung Cancer

    phase 3 mab active

    2 trials

  14. JNJ-77242113, Film-Coated Tablet without JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  15. JNJ-77242113, Film-Coated Tablet without JNJ-77242113, Film-Coated Tablet without Deucravacitinib, DEUCRAVACITINIB

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  16. JNJ-77242113, Icotrokinra, JNJ-77242113-AAC Placebo tablet

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  17. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets, Composition apart from the active substance otherwise to identical to IMP

    Alfasigma S.p.A.

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  18. KAI-9531

    Kailera Therapeutics

    Obesity With Diabetes

    phase 3 small molecule active

    1 trial

  19. KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    3 trials

  20. KAI-9531, KAI-9531, Identical to kai-9531 solution for injection without active drug, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  21. KALOMIN™ Tab.

    United Therapeutics Europe Ltd

    Acute Bronchitis

    phase 3 small molecule completed

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion

    Disc Medicine

    Patients with advanced, metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.

    phase 3 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Epacadostat, CETUXIMAB , Epacadostat, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , FLUOROURACIL

    Incyte

    Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies

    phase 3 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMBROLIZUMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline bag, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Ficerafusp Alfa, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Ficerafusp A

    Bicara Therapeutics

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources